FMI appoints Catherine Polley as VP of pharmacy services
ARLINGTON, Va. The Food Marketing Institute welcomed Catherine Polley, a veteran leader in the pharmacy industry, to the position of FMI vice president of pharmacy services. Polley will spearhead FMI’s new pharmacy public affairs program, launched this year to strengthen industry advocacy on federal pharmacy policy.
Most recently Polley was chief policy officer and senior vice president of government and professional affairs at the American Pharmacists Association. In 2006, she was co-president of the Coalition for Community Pharmacy Action, composed of the National Association of Chain Drug Stores and National Community Pharmacists Association.
“Cathy is a superb choice to lead our pharmacy initiative,” said FMI president and chief executive officer Tim Hammonds. “She is a dedicated pharmacist and an experienced government affairs professional on pharmacy issues. Cathy is a forceful advocate for community pharmacies, including more than 19,000 operated by FMI member companies.”
Polley, a 25-year veteran in the industry, worked for six years as NACDS vice president of state government affairs. She served on the association’s Strategic Planning Committee, educated lawmakers and the media about industry issues and policies, and trained pharmacy employees to become stronger advocates.
She spent 18 years at the Kmart Corporation after receiving a B.S. in pharmacy from the University of Michigan, rising from pharmacy manager to director of pharmacy government and trade relations.
As FMI’s vice president of pharmacy services starting mid-September, Polley will build its new pharmacy advocacy program, working closely with senior public affairs executives and the association’s Pharmacy Affairs Council. FMI created this program with the goal of ensuring that federal laws and regulations recognize the important role that community pharmacies—including supermarket pharmacies—play in the nation’s healthcare system.
Teva receives final FDA approval for generic Famvir, but will delay marketing until patent hearing
JERUSALEM Teva Pharmaceuticals has been granted final approval on its application to market famciclovir, the generic version of Novartis’ Famvir in the 125, 250 and 500mgs.
Now with the approval from the Food and Drug Administration, Teva is also awarded a 180-day period of market exclusivity. But the company will hold off marketing the item until at least Sept. 5, 2007.
On that day, a hearing will be held involving a patent infringement suit brought against Teva regarding the famciclovir. The hearing is scheduled to meet at the U.S. District Court for the District of New Jersey regarding Novartis’ motion for a preliminary injunction. Therefore, both parties have agreed to not launch a generic version of Famvir until after the hearing.
Forest, Daiichi Sankyo sign agreement for Azor
NEW YORK Forest Laboratories and Daiichi Sankyo have signed a co-promotional agreement for Daiichi Sankyo’s new antihypertension drug Azor. Azor is a combination of the calcium channel blocker amlodipine besylate and the angiotensin receptor blocker olmesartan medoxomil.
Under the agreement, Forest will pay Daiichi Sankyo an upfront payment of $20 million and will receive a payment based upon product sales. The agreement is for three years, after which, Daiichi Sankyo will make residual payments to Forest.
The drug is still under review by the Food and Drug Administration with a decision expected by late September. Hypertension affects roughly 72 million people in the U.S., with about 65 percent of those diagnosed having trouble keeping it under control.